|
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.
|
19891708 |
2010 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using patient-derived organoids and xenografts established from an HER2-A775_G776YVMA-inserted advanced lung adenocarcinoma patient sample, we investigated the antitumor activity of pyrotinib.
|
30596880 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in EGFR, KRAS, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), and BRAF; gene fusions involving anaplastic lymphoma receptor tyrosine kinase gene (ALK), ROS1, and ret proto-oncogene (RET); and Met Proto-Oncogene Tyrosine Kinase (MET) exon 14 skipping were the major drivers in LUAD in Asians, exhibiting mutually exclusive and differing prevalence from those reported in studies of LUAD in non-Asians.
|
27615396 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in human epidermal growth factor receptor 2 (HER2; also known as ERBB2) are found in approximately 2% of lung adenocarcinomas.
|
31469421 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, our clinical study indicates that co-overexpression of Her2 with GEP100 in primary lung adenocarcinomas of patients is correlated with the presence of their node-metastasis with a statistical significance.
|
21966491 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we sought to characterize tumor proteome and phosphoproteome changes by longitudinal, prospective collection of tumor tissue from an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for over seven years while undergoing HER2-directed therapy in combination with chemotherapy.
|
30617155 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Despite the assay used to determine the HER2 status of lung tumors, all patients with advanced HER2 positive lung adenocarcinoma should be evaluated for treatment with targeted agents.
|
25601485 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of erbB-2 is associated with shortened survival of patients with lung adenocarcinomas.
|
9569041 |
1998 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ANCCA expression was evaluated by immunohistochemistry in 143 surgically resected lung adenocarcinomas and was correlated with clinicopathologic and molecular variables including adenocarcinoma histologic subtypes, tumor, node, metastasis status, relapse-free survival, overall survival, EGFR mutations, KRAS mutations, HER2 mutations and ALK fusions.
|
23775406 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Among the 204 lung ADCs tested, 11 cases (5.4%) carried HER2 exon 20 insertions and 4 cases (2.0%) had BRAF V600E mutation.
|
26102513 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component.
|
30825613 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We investigated clinical and potential molecular factors associated with HER2-mutant lung adenocarcinoma.
|
22071781 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
|
22908275 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Molecular analysis (EGFR, KRAS, BRAF, ALK, HER2) was performed in 44 metastases of lung adenocarcinomas.
|
29852147 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features.
|
15713515 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
For these studies, several human lung adenocarcinoma cell lines were stably and transiently transfected with the anti-erbB-2 sFv gene.
|
8810638 |
1996 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
In subset analyses of individual pathologies, HER2-amplified status (hazard ratio [HR] 2.05, P=.02), BRAF V600+ mutational status (HR 0.33, P=.04), lung adenocarcinoma histology (HR 1.89, P=.04), and ALK rearrangement (HR 6.36, P<.01) were also associated with RN.
|
27742540 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this surgical series, 52 resected lung adenocarcinomas from never-smokers (< 100 cigarettes in a lifetime) at a single institution (Fudan University, Shanghai, China) were analyzed concurrently for mutations in EGFR, KRAS, NRAS, HRAS, HER2, BRAF, ALK, PIK3CA, TP53 and LKB1.
|
20855837 |
2010 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We showed patients with ERBB2-mutated lung adenocarcinoma can respond to targeted therapies, and we identified potential resistance mechanisms upon progression to targeted therapies.
|
28167203 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FGFR4 mutation is analogous to a reported tumor-specific somatic mutation in ERBB2 and is located in the same exon as a previously reported kinase domain mutation in FGFR4 (Pro712Thr) in a lung adenocarcinoma cell line.
|
17487277 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study, the largest to date dedicated to HER2-mutated NSCLC, reinforces the importance of screening for HER2 mutations in lung adenocarcinomas and suggests the potential efficacy of HER2-targeted drugs in this population.
|
23610105 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
|
14744769 |
2004 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We analysed nm23, c-erbB-2 and p53 protein expression in lung adenocarcinoma in relation to clinicopathological status and patient survival, to elucidate any potential prognostic value.
|
9196297 |
1997 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We conclude that c-erbB-2 expression is different in SCLC compared to NSCLC and high expression of c-erbB-2 is consistently present in lung adenocarcinomas.
|
2569928 |
1989 |